## ADPT: Adaptive Biotechnologies Corpor - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -16.5% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-7.2% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($12.44)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 8
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. Adaptive Biotechnologies to Discuss clonoSEQ Technology and Minimal Residual Disease at Jefferies Fireside Chat**
- Source: Quiver Quantitative | 20251209T220947 | Neutral | Relevance: 99%
- Adaptive Biotechnologies will partake in a Jefferies fireside chat on December 11, 2025, to delve into Minimal Residual Disease (MRD) in Hematology/Oncology and their clonoSEQ assay technology. Dr. Harlan Robins and Susan Bobulsky will represent the company, which specializes in translating the genetics of the adaptive immune system into clinical products for diagnosing and treating diseases like cancer and autoimmune disorders. This event aims to highlight their innovative diagnostics and commitment to personalized immune-driven therapies, though it lacks new specific disclosures or financial updates.

**2. Adaptive Biotechnologies chief commercial officer sells $212k in stock**
- Source: Investing.com | 20251209T000947 | Neutral | Relevance: 99%
-  Adaptive Biotechnologies' Chief Commercial Officer, Sharon Benzeno, sold over $212,000 worth of company stock on December 4, 2025, while also exercising options to acquire shares. These transactions were executed under a pre-arranged trading plan, and Benzeno now directly owns 296,791 shares of the company. This comes after Adaptative Biotechnologies exceeded Q3 2025 earnings and revenue forecasts, despite a recent stock price dip.

**3. Adaptive Biotechnologies Stock Declines After Insider Sale**
- Source: www.timothysykes.com | 20251207T162227 | Neutral | Relevance: 99%
-  Adaptive Biotechnologies (ADPT) stock declined by 15.52% following an insider share sale by CEO Chad M. Robins, amid market uncertainty and underperformance against Healthcare benchmarks. The company faces significant financial struggles with negative EBIT and profit margins, high debt-equity, and inefficiencies in converting investments into financial performance despite a robust current ratio and some revenue growth. This insider activity, combined with adverse financial indicators, contributes to market skepticism and a cautious outlook for the stock.

**4. Adaptive Biotechnologies CEO Chad M Robins Sells $3M in Company Shares**
- Source: StocksToTrade | 20251207T212227 | Neutral | Relevance: 98%
- Adaptive Biotechnologies (ADPT) CEO Chad M. Robins sold over $3 million in company shares in recent weeks, including 160,734 shares in early December and 89,265 shares in mid-November. This insider selling coincides with a -15.52% stock decline and financial metrics showing operational inefficiencies despite strong revenue growth and liquidity. Analysts maintain a cautiously bearish outlook due to negative profit margins, high P/S ratio, and underperforming capital utilization.

**5. Insider Sell: Harlan Robins Sells 37,212 Shares of Adaptive Biotechnologies Corp (ADPT)**
- Source: GuruFocus | 20251207T001016 | Neutral | Relevance: 98%
-  Harlan Robins, Chief Scientific Officer at Adaptive Biotechnologies Corp (ADPT), sold 37,212 shares of the company on December 4, 2025. This transaction increases his total holdings to 1,232,312 shares. The stock is considered significantly overvalued based on its GuruFocus Value, with a price-to-GF-Value ratio of 2.1.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-11 | Morgan Stanley | $16 | $11 | +45% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-11 | Morgan Stanley | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($1.13M) |
| Sells | 11 ($5.21M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Viking Global Invest: 19.7% (0.0%)
- Blackrock Inc.: 8.8% (-2.3%)
- Vanguard Group Inc: 7.4% (-0.0%)
- Ameriprise Financial: 3.9% (+84.3%)
- Sumitomo Mitsui Trus: 2.4% (-15.1%)

### Key Risks

1. High beta (2.20) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Momentum deterioration: MRS_10 falling (-7.2% 5d) with bearish MACD, trend may be turning.
3. Insider selling cluster: $5.2M in recent transactions.
4. Elevated short interest (8.7%): bears positioning against stock.
5. Near-term weakness: 8.8% below SMA50 despite long-term uptrend.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.57 indicates undervaluation relative to growth. Balance sheet: strong liquidity (3.4x). Analyst sentiment positive (1 raises, avg +45%). Insider selling cluster ($5.2M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.3B |
| Beta | 2.20 |
| 52W Range | $5.80 - $20.76 |
| Short Interest | 8.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.57 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 deteriorating from -9.3% to -16.5% (-7.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 19.5pp (needs >3.0% for momentum thesis). Underperforming sector by 11.9pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.27x) but short-term weakness (below SMA20). RSI neutral at 41.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -16.46% (CS: 0) | Weak |
| RSI_14 | 40.6 | Neutral |
| MACD Histogram | -0.42 | Bearish |
| vs SMA20 | 0.896x | Below |
| vs SMA50 | 0.912x | Below |
| vs SMA200 | 1.271x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $14.86
- **Stop Loss:** $12.44 (16.3% risk)
- **Target:** $17.28 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 123
- **Position Value:** $1,827.78
- **Portfolio %:** 1.83%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-10 (Est: $-0.18)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.14 | $0.06 | +143.3% |
| 2025Q2 | $-0.24 | $-0.17 | +28.6% |
| 2025Q1 | $-0.31 | $-0.20 | +35.5% |
| 2024Q4 | $-0.24 | $-0.23 | +5.2% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*